Neurim Pharmaceuticals: EMA committee recommends approval of Neurim Pharma's Slenyto to treat insomnia in children with NGDs
Neurim Pharmaceuticals (Neurim) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending an
Read full article »
Neurim is engaged in the development of drug therapies for the treatment of age-related disorders.
Read more